An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis

References

• RudwaleitMLandewéRvan der HeijdeDThe development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisalAnn Rheum Dis20096877077619297345
   PubMed Web of Science ®Google Scholar
• RudwaleitMvan der HeijdeDLandewéRThe Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in generalAnn Rheum Dis201170253121109520
   PubMed Web of Science ®Google Scholar
• SieperJvan der HeijdeDNon-radiographic axial spondyloarthritis: new definition of an old disease?Arthritis Rheum20136554355123233285
   PubMed Web of Science ®Google Scholar
• WardMMDeodharAAklEAAmerican College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondy-loarthritisArthritis Rheumatol20166828229826401991
   PubMed Web of Science ®Google Scholar
• DeodharAReveilleJDvan den BoschFThe concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the assessment of SpondyloArthritis international society in response to the US Food and Drug Administration’s comments and concernsArthritis Rheumatol2014662649265625154344
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [webpage on the Internet]Committee for Medicinal Products for Human Use2015Summary of opinion (post authorisation): Simponi (golimumab); 2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000992/WC500187055.pdfAccessed May 21, 2015
   Google Scholar
• van der HeijdeDDijkmansBGeusensPAnkylosing spondylitis study for the evaluation of recombinant infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)Arthritis Rheum20055258259115692973
   PubMed Web of Science ®Google Scholar
• van der HeijdeDKivitzASchiffMHATLAS Study GroupEfficacy and safety of adalimumab in patients with ankylosing spondyli-tis: results of a multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheum2006542136214616802350
   PubMed Web of Science ®Google Scholar
• CalinADijkmansBAEmeryPOutcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitisAnn Rheum Dis2004631594160015345498
   PubMed Web of Science ®Google Scholar
• LorenzinMOrtolanAFrallonardoPOlivieroFPunziLRamondaRPredictors of response and drug survival in ankylosing spondylitis patients treated with infliximabBMC Musculoskelet Disord20151616626205000
   PubMed Web of Science ®Google Scholar
• SpadaroALubranoEMarchesoniARemission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre studyRheumatology (Oxford)2013521914191923878312
   PubMed Web of Science ®Google Scholar
• ParkWYooDHJaworskiJComparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyArthritis Res Ther2016182526795209
   PubMed Web of Science ®Google Scholar
• HaibelHRudwaleitMListingJEfficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-twoArthritis Rheum2008581981199118576337
   PubMed Web of Science ®Google Scholar
• BarkhamNKeenHICoatesLCClinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitisArthritis Rheum20096094695419333933
   PubMed Web of Science ®Google Scholar
• SieperJvan der HeijdeDDougadosMEfficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Ann Rheum Dis20137281582222772328
   PubMed Web of Science ®Google Scholar
• DougadosMvan der HeijdeDSieperJSymptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheumatol2014662091210224891317
   PubMed Web of Science ®Google Scholar
• LandewéRBraunJDeodharAEfficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 studyAnn Rheum Dis201473394724013647
   PubMed Web of Science ®Google Scholar
• SieperJvan der HeijdeDDougadosMA randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritisArthritis Rheumatol2015672702271226139307
   PubMed Web of Science ®Google Scholar
• LubranoEPerrottaFMMarchesoniARemission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter studyJ Rheumatol20154225826325512483
   PubMed Web of Science ®Google Scholar
• CorliJFlipoRMPhilippePTumor necrosis factor-α inhibition in ankylosing spondylitis and nonradiographic axial spondyloarthritis: treatment response, drug survival, and patient outcomeJ Rheumatol2015422376238226568593
   PubMed Web of Science ®Google Scholar
• InmanRDDavisJCJrHeijdeDVEfficacy and safety of goli-mumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trialArthritis Rheum2008583402341218975305
   PubMed Web of Science ®Google Scholar
• van der HeijdeDDeodharABraunJGO-RAISE InvestigatorsThe effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trialJ Rheumatol2014411095110324737912
   PubMed Web of Science ®Google Scholar
• DeodharABraunJInmanRDGolimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE studyAnn Rheum Dis20157475776125387477
   PubMed Web of Science ®Google Scholar
• SongIHWeißAHermannKGSimilar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trialAnn Rheum Dis20137282382523172749
   PubMed Web of Science ®Google Scholar
• SieperJLenaertsJWollenhauptJEfficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1Ann Rheum Dis20147310110723696633
   PubMed Web of Science ®Google Scholar
• DeodharAStrandVKayJBraunJThe term non-radiographic axial spondyloarthritis is much more important to classify to diagnose patient with axial spondyloarthritisAnn Rheum Dis20167579179426768406
   PubMed Web of Science ®Google Scholar